A transformative solution for cervical screening in the UK

The UK's cervical screening program faces challenges such as a shrinking workforce, growing backlogs, and declining service quality. Digital cytology offers a promising solution to improve lab workflows, enhance patient care, and address staffing shortages. Already in use across Europe, Australia, New Zealand, and approved by the U.S. FDA, its adoption in the UK has been slow due to funding, implementation, and communication barriers. This policy paper highlights the benefits of digital cytology, explores obstacles to its wider adoption, and provides recommendations to accelerate its integration into the National Screening Program for more effective cervical cancer prevention.

This resource is shared as part of the global #CLINICAL24 conversation